210 related articles for article (PubMed ID: 35074585)
21. Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
Duman RS; Shinohara R; Fogaça MV; Hare B
Mol Psychiatry; 2019 Dec; 24(12):1816-1832. PubMed ID: 30894661
[TBL] [Abstract][Full Text] [Related]
22. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
Rajagopal L; Burgdorf JS; Moskal JR; Meltzer HY
Behav Brain Res; 2016 Feb; 299():105-10. PubMed ID: 26632337
[TBL] [Abstract][Full Text] [Related]
23. Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model.
Abdoulaye IA; Wu SS; Chibaatar E; Yu DF; Le K; Cao XJ; Guo YJ
Neural Plast; 2021; 2021():6635084. PubMed ID: 33981335
[TBL] [Abstract][Full Text] [Related]
24. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2
Fukumoto K; Fogaça MV; Liu RJ; Duman C; Kato T; Li XY; Duman RS
Proc Natl Acad Sci U S A; 2019 Jan; 116(1):297-302. PubMed ID: 30559184
[TBL] [Abstract][Full Text] [Related]
25. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.
Autry AE; Adachi M; Nosyreva E; Na ES; Los MF; Cheng PF; Kavalali ET; Monteggia LM
Nature; 2011 Jun; 475(7354):91-5. PubMed ID: 21677641
[TBL] [Abstract][Full Text] [Related]
26. NMDA receptor partial agonist GLYX-13 alleviates chronic stress-induced depression-like behavior through enhancement of AMPA receptor function in the periaqueductal gray.
Yang PS; Peng HY; Lin TB; Hsieh MC; Lai CY; Lee AS; Wang HH; Ho YC
Neuropharmacology; 2020 Nov; 178():108269. PubMed ID: 32791085
[TBL] [Abstract][Full Text] [Related]
27. Cell-type specific modulation of NMDA receptors triggers antidepressant actions.
Pothula S; Kato T; Liu RJ; Wu M; Gerhard D; Shinohara R; Sliby AN; Chowdhury GMI; Behar KL; Sanacora G; Banerjee P; Duman RS
Mol Psychiatry; 2021 Sep; 26(9):5097-5111. PubMed ID: 32488125
[TBL] [Abstract][Full Text] [Related]
28. Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain.
Vasilescu AN; Mallien A; Pfeiffer N; Lang UE; Gass P; Inta D
Eur Arch Psychiatry Clin Neurosci; 2021 Dec; 271(8):1587-1591. PubMed ID: 32789675
[TBL] [Abstract][Full Text] [Related]
29. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.
Yao N; Skiteva O; Zhang X; Svenningsson P; Chergui K
Mol Psychiatry; 2018 Oct; 23(10):2066-2077. PubMed ID: 29158578
[TBL] [Abstract][Full Text] [Related]
30. mTORC1-dependent signaling pathway underlies the rapid effect of creatine and ketamine in the novelty-suppressed feeding test.
Pazini FL; Rosa JM; Camargo A; Fraga DB; Moretti M; Siteneski A; Rodrigues ALS
Chem Biol Interact; 2020 Dec; 332():109281. PubMed ID: 33022268
[TBL] [Abstract][Full Text] [Related]
31. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.
Yang C; Yang J; Luo A; Hashimoto K
Transl Psychiatry; 2019 Nov; 9(1):280. PubMed ID: 31699965
[TBL] [Abstract][Full Text] [Related]
32. Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date.
Ragguett RM; Rong C; Kratiuk K; McIntyre RS
Expert Opin Investig Drugs; 2019 Feb; 28(2):113-119. PubMed ID: 30585524
[TBL] [Abstract][Full Text] [Related]
33. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression.
Yang Y; Cui Y; Sang K; Dong Y; Ni Z; Ma S; Hu H
Nature; 2018 Feb; 554(7692):317-322. PubMed ID: 29446381
[TBL] [Abstract][Full Text] [Related]
34. Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests.
Andreasen JT; Gynther M; Rygaard A; Bøgelund T; Nielsen SD; Clausen RP; Mogensen J; Pickering DS
Neurosci Lett; 2013 Jun; 546():6-10. PubMed ID: 23643996
[TBL] [Abstract][Full Text] [Related]
35. How does ketamine elicit a rapid antidepressant response?
Kavalali ET; Monteggia LM
Curr Opin Pharmacol; 2015 Feb; 20():35-9. PubMed ID: 25462290
[TBL] [Abstract][Full Text] [Related]
36. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
Monteggia LM; Zarate C
Curr Opin Neurobiol; 2015 Feb; 30():139-43. PubMed ID: 25562451
[TBL] [Abstract][Full Text] [Related]
37. Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.
Kim JW; Monteggia LM
Behav Brain Res; 2020 Feb; 380():112378. PubMed ID: 31760154
[TBL] [Abstract][Full Text] [Related]
38. The antidepressant actions of ketamine and its enantiomers.
Johnston JN; Henter ID; Zarate CA
Pharmacol Ther; 2023 Jun; 246():108431. PubMed ID: 37146727
[TBL] [Abstract][Full Text] [Related]
39. Resolvin D1 and D2 Reverse Lipopolysaccharide-Induced Depression-Like Behaviors Through the mTORC1 Signaling Pathway.
Deyama S; Ishikawa Y; Yoshikawa K; Shimoda K; Ide S; Satoh M; Minami M
Int J Neuropsychopharmacol; 2017 Jul; 20(7):575-584. PubMed ID: 28419244
[TBL] [Abstract][Full Text] [Related]
40. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
